Imaging Pituitary ActiVation by Exendin
NCT03923114 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2024-05-22
Summary
The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist treatment.
Conditions
- Diabetes Mellitus, Type 2
Interventions
- RADIATION
-
Ga-68-NODAGA-exendin-4 PET/CT
PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
Sponsors & Collaborators
-
Radboud University Medical Center
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-23
- Primary Completion
- 2024-04-03
- Completion
- 2024-04-03
Countries
- Netherlands
Study Locations
More Related Trials
-
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
NCT00747968 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
GLP-1 Receptor Expression in CHI
NCT03768518 ·Status: UNKNOWN
-
A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass
NCT04615910 ·Status: RECRUITING ·Phase: PHASE2
-
Cardiovascular Effects of GLP-1 Receptor Activation
NCT03101930 ·Status: COMPLETED ·Phase: PHASE4
-
Beta Cell Imaging During and Shortly After the Honeymoon Phase of T1D
NCT03917238 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
GLP-1 REceptor Agonists and Real World EvIdeNce
NCT03959865 ·Status: UNKNOWN
-
Glucagon Like Peptide-1 in Remote Ischemic Conditioning
NCT02746757 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of 18F-Exendin-4 in Insulinoma
NCT07340437 ·Status: COMPLETED
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients
NCT02847403 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function
NCT02584075 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
NCT01185119 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
11C-5-HTP PET in Clinical Islet Transplantation
NCT02689479 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
NCT02639130 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
NCT02104739 ·Status: COMPLETED ·Phase: PHASE4
-
The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus
NCT02413762 ·Status: COMPLETED
-
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
NCT01843881 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01449019 ·Status: COMPLETED ·Phase: PHASE1
-
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
NCT04034524 ·Status: UNKNOWN
-
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
NCT01900340 ·Status: COMPLETED ·Phase: PHASE1
-
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
NCT02664441 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
NCT07029412 ·Status: RECRUITING ·Phase: PHASE2
-
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718 ·Status: COMPLETED ·Phase: NA
-
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832 ·Status: RECRUITING ·Phase: NA
-
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
NCT03241303 ·Status: COMPLETED ·Phase: NA